Background

Messenger RNA (mRNA) vaccines have demonstrated clinical value during the COVID-19 pandemic, but the proportion of administered mRNA that is effectively used for protein synthesis remains limited. mRNA is easily degraded in body fluids and struggles to cross the cell membrane, necessitating delivery via lipid nanoparticles (LNPs). However, even after cellular uptake, a significant portion of LNPs becomes trapped in endosomes and is subsequently degraded in lysosomes. Since only mRNA that reaches the cytosol can be translated into antigenic proteins by ribosomes, endosomal escape is a critical bottleneck in delivery efficiency.

Previous studies have addressed this issue by modifying the chemical structure and pKa of ionizable lipids, as well as particle size and lipid composition. However, developing new lipids and validating their toxicity and manufacturability from scratch can be burdensome. The research team opted to combine a nitric oxide (NO) generating component with an ionizable lipid-based LNP, SM-102, already used in approved mRNA vaccines. This approach aims to reinforce the intracellular release step while maintaining the validated delivery framework.

Key Findings

Among the candidates evaluated, SM-102/DEA LNPs were selected as the lead formulation. DEA is a component that releases NO, and this formulation significantly enhanced mRNA delivery in both cell and animal models compared to standard SM-102 LNPs. The comparison with SM-102, a formulation used in FDA-approved mRNA vaccines, provides a more rigorous benchmark than comparisons with experimental LNPs.

The key innovation lies not only in increasing the amount of particle uptake but also in facilitating the movement of mRNA to the functional cytosolic compartment. By integrating NO-generating components into LNPs, the research team modulated intracellular delivery barriers, resulting in increased protein expression of the encapsulated mRNA. Another distinguishing feature is the expansion of the existing SM-102 platform without introducing new polymers or entirely new ionizable lipids.

The researchers further encapsulated mRNA encoding the SARS-CoV-2 spike protein into both formulations and administered them via intramuscular injection. In the SM-102/DEA LNP group, anti-spike immunoglobulin G (IgG) antibody levels were significantly higher than in the standard SM-102 LNP group, and a robust CD8 T-cell immune response was also observed. This indicates that the increased delivery translated into enhanced humoral and cellular immunity, rather than merely a reporter signal. However, the abstract did not provide fold increases, animal numbers, dose amounts, or follow-up periods, so the magnitude and reproducibility of the effects require further evaluation based on the original data.

Implications and Outlook

This study suggests the potential of using NO as an adjunct component in mRNA delivery systems. If the same amount of mRNA can express more antigen, it may allow for reduced vaccine dosing or improved responses to weakly immunogenic antigens. The enhancement of both antibody and CD8 T-cell responses is particularly promising not only for infectious disease vaccines but also for cancer vaccines that express tumor neoantigens.

There are still many steps to overcome before clinical application. NO can have diverse biological effects depending on its concentration and release location, including vasodilation, oxidative/nitrosative stress, and inflammation modulation. The release rate and in vivo distribution of DEA, repeat-dose toxicity, and the storage stability of LNPs must be clarified. It also needs to be confirmed whether the SM-102/DEA formulation can be mass-produced using the same process as existing LNPs and whether the dose-sparing effect is maintained in humans. Subsequent studies validating efficacy and safety across multiple antigens and animal species will be crucial for clinical translation.